Omadacycline - Paratek Pharmaceuticals

Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tufts University
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Community-acquired pneumonia; Skin and soft tissue infections
  • Phase II Cystitis; Pyelonephritis; Urinary tract infections
  • Preclinical Acute sinusitis; Anthrax; Plague
  • Discontinued Nosocomial infections

Most Recent Events

  • 08 Oct 2018 Discontinued - Phase-I for Nosocomial infections in USA and United Kingdom (IV) (Paratek pipeline, October 2018)
  • 08 Oct 2018 Preclinical trials in Anthrax in USA (PO), before October 2018 (Paratek pipeline, October 2018)
  • 08 Oct 2018 Preclinical trials in Plague in USA (PO), before October 2018 (Paratek pipeline, October 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top